Netherlands-Linked Biotechnology Deal Highlights Advanced Healthcare Investment

Healthcare innovation remains an important investment area for Dutch-linked businesses and international biotechnology companies. On 16 October 2026, Mankind Pharma announced an agreement to acquire a 70% stake in Belgian cell-therapy developer Armed Cell Therapeutics for €48 million through its Netherlands subsidiary. The announced transaction is subject to applicable approvals. Healthcare providers and medical technology companies require data integration, operational analytics and reliable systems for managing complex services. The €48 million figure refers to the proposed acquisition, not an HPC implementation fee or a Dutch healthcare procurement contract.